Ironwood is evaluating products in the diabetes and cardiovascular spaces, with a promising product candidate being investigated in Phase II clinical studies as a potential treatment for diabetic nephropathy, a significant complication of diabetes, as well as a potential treatment for heart failure with preserved ejection fraction.
Comments:
No comments yet... Be the first!
Post your comment:
Your comment has been sent and is waiting for approval to be displayed.
Your comment cannot be sent. Please try again.
"WebsEdge was a great team to work with. They covered our 101st Annual Meeting and did a great job at capturing the message we wanted to convey to our attendees. Seemless process prior, during and after the meeting."